Valuation: PROT DIAG

Market Cap 225M 23.13M 20.33M 18.93M 17.38M 32.64M 2.22B 33.07M 87.88M 1.1B 86.83M 84.96M 3.79B P/E 2024
-2.94x
P/E 2025 -4.28x
Enterprise Value 184M 18.96M 16.66M 15.51M 14.25M 26.75M 1.82B 27.1M 72.02M 898M 71.16M 69.63M 3.1B EV / Sales 2024
2.16x
EV / Sales 2025 4.15x
Free-Float
12.26%
Yield 2024 *
-
Yield 2025 -
1 day-6.85%
1 week+10.27%
Current month+35.94%
1 month+29.85%
3 months+17.89%
6 months-7.45%
Current year-2.79%
1 week 17.4
Extreme 17.4
18.68
1 month 12.5
Extreme 12.5
18.68
Current year 12.46
Extreme 12.46
21
1 year 12.46
Extreme 12.46
27.6
3 years 11.7
Extreme 11.7
142
5 years 11.7
Extreme 11.7
183.4
10 years 11.7
Extreme 11.7
806
Manager TitleAgeSince
Chief Executive Officer 62 30/06/2020
Director of Finance/CFO 68 -
Chief Operating Officer - 31/05/2023
Director TitleAgeSince
Chairman 60 -
Director/Board Member - 30/04/2022
Director/Board Member 62 -
Change 5-day change 1-year change 3-year change Capi.($)
-6.85%+10.27%-29.55%-87.16% 23.2M
-3.03%-11.96%+12.14%-40.07% 15.54B
+4.07%+9.27%+1.83%+92.76% 1.65B
+4.86%+1.51%-35.49%-80.57% 1.09B
+1.20%-3.51%-37.83%+14.00% 948M
+3.70%-2.12%-43.46%-54.33% 609M
+1.10%-4.29%-50.51%-58.91% 505M
+0.55%+3.39%+38.99%-52.28% 460M
+1.49%-2.55%-56.83%-60.34% 365M
+1.29%-3.67%-21.13%-35.69% 344M
Average +1.02%-2.38%-22.19%-36.26% 2.15B
Weighted average by Cap. -0.79%-6.76%+2.52%-31.02%

Financials

2024 2025
Net sales 36.33M 3.73M 3.28M 3.06M 2.81M 5.27M 358M 5.34M 14.19M 177M 14.02M 13.72M 611M 42.2M 4.34M 3.81M 3.55M 3.26M 6.12M 416M 6.2M 16.48M 205M 16.29M 15.93M 710M
Net income -26.94M -2.77M -2.43M -2.27M -2.08M -3.91M -266M -3.96M -10.52M -131M -10.4M -10.17M -453M -49.71M -5.11M -4.49M -4.18M -3.84M -7.21M -490M -7.31M -19.41M -242M -19.18M -18.77M -836M
Net Debt -15.73M -1.62M -1.42M -1.32M -1.22M -2.28M -155M -2.31M -6.15M -76.6M -6.07M -5.94M -265M -40.61M -4.17M -3.67M -3.42M -3.14M -5.89M -400M -5.97M -15.86M -198M -15.67M -15.33M -683M
Logo PROT DIAG
Prolight Diagnostics AB (publ) is a Sweden-based medical technology company. Together with Technology Partners, the Company develops patient-close test systems based on patented technology, for use in so-called Point of Care Testing (POCT). POCT tests are performed outside the traditional hospital laboratory, small mobile instruments enable testing near the patient and provide quick test answers. The Company focuses on the heart marker troponin.
Employees
22
Date Price Change Volume
26/07/26 SEK 17.40 -6.85% 16,863
24/07/26 SEK 18.68 +1.52% 5,384
23/07/26 SEK 18.40 -0.33% 15,198
22/07/26 SEK 18.46 +2.56% 9,543
21/07/26 SEK 18.00 +6.64% 21,465
  1. Stock Market
  2. Stocks
  3. PRLD Stock